PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia

Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) comprises ∼10% to 15% of childhood ALL cases, many of which respond exquisitely to tyrosine kinase inhibitors (TKIs), for example, imatinib in PDGFRB-rearranged ALL. However, some cases developed drug resistance to TKIs and the mec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Zhang, Yingchi, Gao, Yufeng, Zhang, Hui, Zhang, Jingliao, He, Fuhong, Hnízda, Aleš, Qian, Maoxiang, Liu, Xiaoming, Gocho, Yoshihiro, Pui, Ching-Hon, Cheng, Tao, Wang, Qianfei, Yang, Jun J., Zhu, Xiaofan, Liu, Xin
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5958655/
https://ncbi.nlm.nih.gov/pubmed/29434033
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-11-817510
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados